HUTCHMED (China) (HMDCF) Long-Term Debt Repayments (2018)
HUTCHMED (China)'s (HMDCF) quarterly Long-Term Debt Repayments came in at $60.0 million in Q4 2018.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Long-Term Debt Repayments (2018) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Long-Term Debt Repayments for 1 consecutive years, with $60.0 million the latest figure, recorded in Q4 2018.
- On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to $60.0 million in Q4 2018; TTM through Dec 2019 was $60.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$24.6 million, up 19.46% from the prior year.
- Long-Term Debt Repayments was $60.0 million for Q4 2018 at HUTCHMED (China).
- Over five years, Long-Term Debt Repayments peaked at $60.0 million in Q4 2018 and troughed at $60.0 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |